Steadybase.

Legend Biotech Corp.

Website LinkedIn
  • LEGN ยท Nasdaq
  • Pharmaceutical Preparations
  • Somerset, NJ
  • 2,900 employees
  • CIK 0001801198

Updated from SEC filings through

Top things to know

Executives

Legend Biotech Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Somerset, NJ. It trades as LEGN on Nasdaq. Revenue was $627M in the fiscal year ending December 31, 2024, +120.0% from the year before. It reported about 2,900 employees. Ingrid Zhang is Chief Executive Officer.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue Not on file $627M
20-F, 2025-03-11
$285M
20-F, 2025-03-11
$117M
20-F, 2025-03-11
$68.8M
20-F, 2024-03-19
Operating income -$137M
20-F, 2026-03-10
-$310M
20-F, 2026-03-10
-$528M
20-F, 2026-03-10
Not on file Not on file
SG&A Not on file Not on file Not on file Not on file Not on file
Net income -$297M
20-F, 2026-03-10
-$177M
20-F, 2026-03-10
-$518M
20-F, 2026-03-10
-$446M
20-F, 2025-03-11
-$404M
20-F, 2024-03-19

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Ingrid Zhang Ingrid Zhang Chief Executive Officer Form 4, September 16, 2026
Alan Bash Alan Bash
Interim Chief Executive Officer at Legend Biotech
Interim CEO Form 4, August 18, 2026
Ying Huang Chief Executive Officer Form 4, July 2, 2026
Carlos E. Santos Carlos E. Santos
Chief Financial Officer
Chief Financial Officer Form 4, September 23, 2026

What Legend Biotech Corp does

We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 2,900 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 369.9 million (as of December 31, 2025) 20-F, March 10, 2026
Auditor Ernst & Young LLP (Iselin, New Jersey) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
November 17, 2026 Ingrid Zhang
Chief Executive Officer
Buy 20,000 $163K Form 4, November 20, 2026
November 13, 2026 Peter Salovey
Director
Buy 20,000 $183K Form 4, November 16, 2026
September 29, 2026 Corazon (Corsee) D. Sanders
Director
Sale 27,370 $259K Form 4, October 1, 2026
September 21, 2026 Carlos E. Santos
Chief Financial Officer
Sale 5,430 $50K Form 4, September 23, 2026
June 30, 2026 Patrick John Casey
Director
Sale 6,000 $89K Form 4, July 2, 2026
June 25, 2026 Ying Huang
Chief Executive Officer
Sale 5,566 $82K Form 4, June 29, 2026
March 25, 2026 Ying Huang
Chief Executive Officer
Sale 9,936 $87K Form 4, March 27, 2026

Recent 8-K events

No 8-K filings on file.

Frequently asked questions about Legend Biotech Corp

What does Legend Biotech Corp do?
In its own words, from Item 1 of its 10-K: "We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 2,900 employees in the United States, China and Europe, our differentiated technology, global development and manufacturing strategy and expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs."
What is Legend Biotech Corp's revenue?
$627M for the fiscal year ending December 31, 2024, from its 20-F filed March 11, 2025.
Is Legend Biotech Corp profitable?
Legend Biotech Corp reported net income of -$177M for the fiscal year ending December 31, 2024.
How many employees does Legend Biotech Corp have?
About 2,900 as of December 31, 2025, as stated in its annual report.
Who is the CEO of Legend Biotech Corp?
Ingrid Zhang, Chief Executive Officer, as named in a 4 filed September 16, 2026.
Who is the CFO of Legend Biotech Corp?
Carlos E. Santos, Chief Financial Officer, as named in a 4 filed September 23, 2026.
Where is Legend Biotech Corp headquartered?
Somerset, NJ.
What is Legend Biotech Corp's stock ticker?
LEGN on Nasdaq.
What industry is Legend Biotech Corp in?
Pharmaceutical Preparations, SIC code 2834.
What is Legend Biotech Corp's website?
legendbiotech.com.
When does Legend Biotech Corp report earnings next?
February 10, 2027. This is an estimate from past filing dates, not a confirmed date.
Is Legend Biotech Corp a public company?
Yes. Legend Biotech Corp files with the SEC under CIK 0001801198 and trades as LEGN.
Who audits Legend Biotech Corp?
Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
How many shares of Legend Biotech Corp are outstanding?
369.9 million shares as of December 31, 2025, from its 20-F filed March 10, 2026.
Have Legend Biotech Corp insiders traded stock recently?
Since March 25, 2026, officers and directors reported 5 open-market sales worth about $567K and 2 purchases worth about $346K on Forms 4 and 5. The most recent: Ingrid Zhang (Chief Executive Officer) bought 20,000 shares on November 17, 2026.